Hematologic Malignancy
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
CI-CAN-00005967PTCLExplore in graph →
Hematologic172 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005967PTCLExplore in graph →
Clinical trials
786 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (129)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02753543 | Chidamide Plus Chemotherapy in the Treatment of Peripheral T-cell Lymphoma | unknown | Phase 2 | 33 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT03340155 | Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases(BioUV2017) | unknown | N/A | 240 | Medical University of GrazOTHER | 1 | Nov 13, 2017 | clinicaltrials |
| NCT03154918 |
| GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma |
| unknown |
| Phase 2 |
| 60 |
| Sichuan UniversityOTHER |
| 1 |
| Nov 8, 2017 |
| clinicaltrials |
| NCT03321890 | Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | unknown | Phase 2 | 102 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2017 | clinicaltrials |
| NCT03273452 | Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)(PET) | unknown | Phase 2 | 30 | Qingdao UniversityOTHER | 1 | Sep 25, 2017 | clinicaltrials |
| NCT03267407 | Vietnam Cryptococcal Retention in Care Study - Version 2.1 | unknown | — | 1,184 | National Hospital for Tropical Diseases, Hanoi, VietnamOTHER_GOV | 1 | Sep 12, 2017 | clinicaltrials |
| NCT03268889 | Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)(CHOP) | unknown | N/A | 39 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT03150602 | A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy | unknown | Phase 4 | 22 | Taiwan Mundipharma Pharmaceuticals Ltd.INDUSTRY | 1 | May 12, 2017 | clinicaltrials |
| NCT03107962 | Treatment of Relapsed or Refractory Natural Killer/T Cell Lymphoma | unknown | Phase 2 | 20 | Mingzhi ZhangOTHER | 1 | Apr 11, 2017 | clinicaltrials |
| NCT03000738 | The Value and Mechanisms for Monocytes Subpopulations in Predicting the Prognosis of Lymphomas | unknown | — | 100 | Peking Union Medical College HospitalOTHER | 0 | Mar 31, 2017 | clinicaltrials |
| NCT03079947 | Effectiveness of Circulating DNA for Predicting the Relapse and Overall Survival in NHL Patients | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Mar 27, 2017 | clinicaltrials |
| NCT03051542 | Evaluating 18F-FDG PET/CT With Liver SUVmax-based Criteria for Prognosis of Patients With Natural Killer/T-cell Lymphoma | unknown | N/A | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT03051555 | 18F-FDG PET/CT-based Prognostic Model for Predicting Outcome in Patients With Natural Killer/T-cell Lymphoma | unknown | N/A | 60 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 13, 2017 | clinicaltrials |
| NCT03023358 | Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients | unknown | Phase 3 | 174 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jan 18, 2017 | clinicaltrials |
| NCT02742727 | CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 6, 2016 | clinicaltrials |
| NCT02944812 | Chidamide for Refractory/Relapsed Peripheral T Cell Lymphoma | unknown | Phase 2 | 12 | Guangdong Provincial People's HospitalOTHER | 1 | Oct 26, 2016 | clinicaltrials |
| NCT02213861 | Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma | unknown | Phase 2 | 60 | TetraLogic PharmaceuticalsINDUSTRY | 1 | Oct 20, 2016 | clinicaltrials |
| NCT02881749 | Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides | unknown | Phase 2 | 68 | Thomas Jefferson UniversityOTHER | 0 | Aug 30, 2016 | clinicaltrials |
| NCT02878278 | Differences Between Chidamide Taken Daily and Twice a Week in Therapeutic Effect，Pharmacokinetics, Pharmacodynamics and EB Virus Activation | unknown | Phase 2 | 24 | Huiqiang HuangOTHER | 0 | Aug 25, 2016 | clinicaltrials |
| NCT02856997 | Chidamide With ICE Regimen for Relapsed/Refractory Peripheral T Cell Lymphoma | unknown | Phase 2 | 35 | Yuankai ShiOTHER | 0 | Aug 5, 2016 | clinicaltrials |
| NCT02080234 | Combine GELOX With Concurrent Radiation Therapy for Patients With Stage IE/IIE ENKTL | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02539472 | Early Diagnosis of Mycosis Fungoides(DIAPREMYF) | unknown | N/A | 620 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Apr 18, 2016 | clinicaltrials |
| NCT02520219 | Endostar Aggressive Treatment of Peripheral T-cell Lymphoma (PTCL) Phase II Clinical Study | unknown | Phase 2 | 60 | Nanjing NingQi Medicine Science and Technology Co., Ltd.INDUSTRY | 1 | Aug 11, 2015 | clinicaltrials |
| NCT01501136 | Treatment of Natural Killer/T Cell Lymphoma-I/II(CTTNKTL-I/II) | unknown | Phase 4 | 200 | Mingzhi ZhangOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT01501149 | Treatment of Natural Killer/T Cell Lymphoma-Ⅲ/Ⅳ(CTTNKTL-Ⅲ/Ⅳ) | unknown | Phase 4 | 80 | Mingzhi ZhangOTHER | 1 | Jul 17, 2015 | clinicaltrials |
| NCT02039895 | Helical Irradiation of Total Skin (HITS) for Cutaneous Lymphoma(HITS) | unknown | N/A | 10 | Far Eastern Memorial HospitalOTHER | 1 | Aug 4, 2014 | clinicaltrials |
| NCT01933282 | MESA Treatment for NK/T Cell Lymphoma(MTN) | unknown | Phase 2 | 100 | Air Force Military Medical University, ChinaOTHER | 1 | Dec 24, 2013 | clinicaltrials |
| NCT00725231 | Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP(A-CHOP-14) | unknown | Phase 3 | 274 | University of GöttingenOTHER | 1 | May 7, 2012 | clinicaltrials |
| NCT01470066 | Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas | unknown | — | 80 | Chonnam National University HospitalOTHER | 1 | Nov 11, 2011 | clinicaltrials |
| NCT01467024 | Evaluation of the MP Diagnostics HTLV Blot 2.4 | unknown | — | 600 | MP Biomedicals, LLCINDUSTRY | 1 | Nov 8, 2011 | clinicaltrials |
| NCT01132989 | Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma(REvMM2009) | unknown | Phase 2 | 10 | Florida Academic Dermatology CentersOTHER | 1 | May 28, 2010 | clinicaltrials |
| NCT00779896 | Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study | unknown | Phase 1 / Phase 2 | 15 | McGill UniversityOTHER | 1 | Oct 24, 2008 | clinicaltrials |
| NCT00157274 | Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome | unknown | Phase 2 | 20 | Latin American Cooperative Onco-Haematology Group - PeruOTHER | 1 | Apr 3, 2007 | clinicaltrials |
| NCT00299351 | A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. | unknown | Phase 2 | 8 | Royal Marsden NHS Foundation TrustOTHER | 0 | Mar 6, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Nov 14, 2017source: clinicaltrials